11:53 AM EDT, 04/02/2024 (MT Newswires) -- Quest Diagnostics ( DGX ) and Broad Clinical Labs said Tuesday they have begun a research collaboration to demonstrate the clinical value of whole genome sequencing as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

The initiative seeks to demonstrate that whole genome sequencing can offer insights from a single blood test that are at least as accurate as conventional tests.

The research involves phenotypic and genotypic data sharing to improve the interpretation of genomic tests and the understanding of development delay, Heidi Rehm, medical director of Broad Clinical Labs, said.

Quest Diagnostics ( DGX ) shares were down 1.8% in recent Tuesday trading.

Price: 132.84, Change: -1.93, Percent Change: -1.43